OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
As part of its OncView™ video series, CancerNetwork® spoke with David H. Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center, Robert S. Alter, MD, of the John Theurer Cancer Center, Arnab Basu, MD, MPH, FACP, of the O’Neal Comprehensive Cancer, Mehmet Asim Bilen, MD, of Winship Cancer Institute, and Chung-Han Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and comment on emerging data in the field.
In the video series, some of the content discussed included:
- Trends in RCC Incidence
- Risk Models and Prognostic Factors
- Biomarker Testing in RCC: Current Approaches
- Comparison of Older First-Line, Single-Agent Therapies
- Newer First-Line Combination Therapy Options
To watch more videos in the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
